Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
08
05
2020
accepted:
05
08
2020
pubmed:
12
9
2020
medline:
15
5
2021
entrez:
11
9
2020
Statut:
ppublish
Résumé
Brodalumab was efficacious and safe in moderate-to-severe plaque-type psoriasis in the AMAGINE trials; published reports under real-life conditions are limited. To evaluate the effectiveness and safety of brodalumab in patients with moderate-to-severe plaque-type psoriasis in a real-world setting. This observational, retrospective study enrolled adult patients (≥18 years) with moderate-to-severe plaque-type psoriasis who underwent 24 weeks of treatment with brodalumab at 17 Italian dermatological centres. Baseline data included demographics, comorbidities, age of onset and duration of psoriasis and previous treatments. Psoriasis Area and Severity Index (PASI), Physician Global Assessment (PGA), static PGA of Genitalia, Dermatology Life Quality Index and patient satisfaction were assessed at weeks 0, 4, 12 and 24; adverse events were recorded. Seventy-eight patients (mean age 47.9 years, 71.8% male, average disease duration 16.8 years) were enrolled. A rapid and significant reduction in mean PASI score was observed after 4 weeks of treatment, decreasing further at weeks 12 and 24 (all P < 0.0001 vs. baseline). A higher number of cardiometabolic comorbidities and previous therapies were negatively associated with the achievement of PASI 90 at all assessments. Brodalumab was effective in bio-experienced patients, including those who had failed on anti-interleukin (IL)-17 therapies. Quality of life and patient satisfaction increased significantly during treatment (P < 0.0001 and P < 0.01 vs. baseline, respectively). Treatment was interrupted in 9 (11.5%) patients due to adverse events (n = 4), lack of efficacy (n = 3), lost to follow-up (n = 1) and surgical procedure (n = 1). Brodalumab is effective and safe in the treatment of moderate-to-severe psoriasis in a real-world setting, including in patients with failure to anti-IL17 therapies.
Sections du résumé
BACKGROUND
BACKGROUND
Brodalumab was efficacious and safe in moderate-to-severe plaque-type psoriasis in the AMAGINE trials; published reports under real-life conditions are limited.
OBJECTIVES
OBJECTIVE
To evaluate the effectiveness and safety of brodalumab in patients with moderate-to-severe plaque-type psoriasis in a real-world setting.
METHODS
METHODS
This observational, retrospective study enrolled adult patients (≥18 years) with moderate-to-severe plaque-type psoriasis who underwent 24 weeks of treatment with brodalumab at 17 Italian dermatological centres. Baseline data included demographics, comorbidities, age of onset and duration of psoriasis and previous treatments. Psoriasis Area and Severity Index (PASI), Physician Global Assessment (PGA), static PGA of Genitalia, Dermatology Life Quality Index and patient satisfaction were assessed at weeks 0, 4, 12 and 24; adverse events were recorded.
RESULTS
RESULTS
Seventy-eight patients (mean age 47.9 years, 71.8% male, average disease duration 16.8 years) were enrolled. A rapid and significant reduction in mean PASI score was observed after 4 weeks of treatment, decreasing further at weeks 12 and 24 (all P < 0.0001 vs. baseline). A higher number of cardiometabolic comorbidities and previous therapies were negatively associated with the achievement of PASI 90 at all assessments. Brodalumab was effective in bio-experienced patients, including those who had failed on anti-interleukin (IL)-17 therapies. Quality of life and patient satisfaction increased significantly during treatment (P < 0.0001 and P < 0.01 vs. baseline, respectively). Treatment was interrupted in 9 (11.5%) patients due to adverse events (n = 4), lack of efficacy (n = 3), lost to follow-up (n = 1) and surgical procedure (n = 1).
CONCLUSIONS
CONCLUSIONS
Brodalumab is effective and safe in the treatment of moderate-to-severe psoriasis in a real-world setting, including in patients with failure to anti-IL17 therapies.
Substances chimiques
Antibodies, Monoclonal
0
Antibodies, Monoclonal, Humanized
0
brodalumab
6ZA31Y954Z
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
693-700Subventions
Organisme : LEO Pharma
Investigateurs
G Pertusi
(G)
E Stroppiana
(E)
A Gambardella
(A)
F Romano
(F)
C Sassetti
(C)
A Carpentieri
(A)
F Bellinato
(F)
M Burlando
(M)
F Graziola
(F)
L Sacchelli
(L)
A Campanati
(A)
G Ronza
(G)
Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 European Academy of Dermatology and Venereology.
Références
Parisi R, Symmons DP, Griffiths CE, Ashcroft DM. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol 2013; 133: 377-385.
Rapp SR, Feldman SR, Exum ML, Fleischer AB, Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401-407.
Gottlieb AB, Dann F. Comorbidities in patients with psoriasis. Am J Med 2009; 122: 1150.e1151-1159.
Mrowietz U, Steinz K, Gerdes S. Psoriasis: to treat or to manage? Exp Dermatol 2014; 23: 705-709.
Ferreira BIRC, Abreu JLPDC, Reis JPGD, Figueiredo AMDC. Psoriasis and associated psychiatric disorders. A systematic review on etiopathogenesis and clinical correlation. J Clin Aesthet Dermatol 2016; 9: 36-43.
Girolomoni G, Strohal R, Puig L et al. The role of IL-23 and the IL-23/TH 17 immune axis in the pathogenesis and treatment of psoriasis. J Eur Acad Dermatology Venereol 2017; 31: 1616-1626.
Marinoni B, Ceribelli A, Massarotti MS, Selmi C. The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications. Autoimmun Highlights 2014; 5: 9-19.
Lowes MA, Kikuchi T, Fuentes-Duculan J et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008; 128: 1207-1211.
Attia A, Abushouk AI, Ahmed H et al. Safety and efficacy of brodalumab for moderate-to-severe plaque psoriasis: a systematic review and meta-analysis. Clin Drug Investig 2017; 37: 439-451.
Lonnberg AS, Zachariae C, Skov L. Targeting of interleukin-17 in the treatment of psoriasis. Clin Cosmet Investig Dermatol 2014; 7: 251-259.
Russell CB, Rand H, Bigler J et al. Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody. J Immunol 2014; 192: 3828-3836.
Papp KA, Leonardi C, Menter A et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012; 366: 1181-1189.
Papp KA, Reich K, Paul C et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol 2016; 175: 273-286.
Lebwohl M, Strober B, Menter A et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med 2015; 373: 1318-1328.
European Medicines Agency. Kyntheum (brodalumab) 210 mg solution for injection in pre-filled syringe: Summary of Product Characteristics. Date of first authorisation: 17 July 2017. URL https://www.ema.europa.eu/en/medicines/human/EPAR/kyntheum (last accessed: 4 March 2020).
Lebwohl MG, Blauvelt A, Menter A et al. Efficacy, safety, and patient-reported outcomes in patients with moderate-to-severe plaque psoriasis treated with brodalumab for 5 years in a long-term, open-label, phase II study. Am J Clin Dermatol 2019; 20: 863-871.
Papp KA, Gordon KB, Langley RG et al. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3. Br J Dermatol 2018; 179: 320-328.
Kimmel G, Chima M, Kim HJ et al. Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed. J Am Acad Dermatol 2019; 81: 857-859.
Blauvelt A, Papp KA, Lebwohl MG et al. Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: A pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3). J Am Acad Dermatol 2017; 77: 372-374.
Papp K, Leonardi C, Menter A et al. Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment. J Am Acad Dermatol 2014; 71: 1183-1190.e1183.
Puig L, Lebwohl M, Bachelez H, Sobell J, Jacobson AA. Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial. J Am Acad Dermatol 2020; 82: 352-359.
Ohata C, Ohyama B, Katayama E, Nakama T. Real-world efficacy and safety of interleukin-17 inhibitors for psoriasis: a single-center experience. J Dermatol 2020; 47: 405-408.
Kishimoto M, Komine M, Kamiya K, Sugai J, Mieno M, Ohtsuki M. Drug survival of biologic agents for psoriatic patients in a real-world setting in Japan. J Dermatol 2020; 47: 33-40.
Pinter A, Bonnekoh B, Hadshiew IM, Zimmer S. Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review. Clin Cosmet Investig Dermatol 2019; 12: 509-517.
Yeung J, Ladda M, Piguet V. Dose optimization of brodalumab in moderate-to-severe plaque psoriasis: a case report. SAGE Open Medical Case Reports 2020; 8: 2050313X20905672.
Kromer C, Wilsmann-Theis D, Gerdes S et al. Changing within the same class: Efficacy of brodalumab in plaque psoriasis after treatment with an IL-17A blocker - a retrospective multicenter study. J Dermatolog Treat 2020. [Epub ahead of print].
Valenti M, Facheris P, Pavia G, Narcisi A, Borroni RG, Costanzo A. A new way to inhibit IL-17 in psoriasis: real-life use of brodalumab goes beyond clinical trials expectations. J Dermatol Res Ther 2019; 5: 075.
Haycraft K, Cooke L. Rapid and sustained improvement in a patient with plaque psoriasis switched to brodalumab after failing treatment clearance on six other biologic therapies. J Drugs Dermatol 2020; 19: 86-88.
Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244.
Langley RG, Ellis CN. Evaluating psoriasis with psoriasis area and severity index, psoriasis global assessment, and lattice system physician's global assessment. J Am Acad Dermatol 2004; 51: 563-569.
Merola JF, Bleakman AP, Gottlieb AB et al. The static physician's global assessment of genitalia: a clinical outcome measure for the severity of genital psoriasis. J Drugs Dermatol 2017; 16: 793-799.
Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
Likert R. A Technique for the measurement of attitudes. Archives of Psychology 1932; 140: 1-55.
International Council for Harmonisation. Guidelines for Good Clinical Practice E6 (R2); 2016. URL https://www.ich.org/ (last accessed: 12 March 2020).
World Medical Association. World Medical Association Declaration Of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013; 310: 2191-2194.
Merola JF, Ghislain PD, Dauendorffer JN et al. Ixekizumab improves secondary lesional signs, pain and sexual health in patients with moderate-to-severe genital psoriasis. J Eur Acad Dermatology Venereol 2020; 34: 1257-1262. [Epub ahead of print].
Yosipovitch G, Foley P, Ryan C et al. Ixekizumab improved patient-reported genital psoriasis symptoms and impact of symptoms on sexual activity vs placebo in a randomized, Double-Blind Study. J Sex Med 2018; 15: 1645-1652.
Ryan C, Menter A, Guenther L et al. Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis. Br J Dermatol 2018; 179: 844-852.
Guenther L, Potts Bleakman A, Weisman J et al. Ixekizumab results in persistent clinical improvement in moderate-to-severe genital psoriasis during a 52 week, randomized, placebo-controlled, phase 3 clinical trial. Acta Derm Venereol 2020; 100: adv00006.
Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes 2012; 2: e54.
Jensen P, Skov L. Psoriasis and Obesity. Dermatology 2016; 232: 633-639.